CA2571218C - Tdf-related compounds and analogs thereof - Google Patents

Tdf-related compounds and analogs thereof Download PDF

Info

Publication number
CA2571218C
CA2571218C CA2571218A CA2571218A CA2571218C CA 2571218 C CA2571218 C CA 2571218C CA 2571218 A CA2571218 A CA 2571218A CA 2571218 A CA2571218 A CA 2571218A CA 2571218 C CA2571218 C CA 2571218C
Authority
CA
Canada
Prior art keywords
amino acid
ser
tdfrp
disease
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2571218A
Other languages
English (en)
French (fr)
Other versions
CA2571218A1 (en
Inventor
William D. Carlson
Peter C. Keck
Michael Sworin
Dattatreymurty Bosukonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrasos Innovation Inc
Original Assignee
Thrasos Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation Inc filed Critical Thrasos Innovation Inc
Priority to CA2897218A priority Critical patent/CA2897218A1/en
Publication of CA2571218A1 publication Critical patent/CA2571218A1/en
Application granted granted Critical
Publication of CA2571218C publication Critical patent/CA2571218C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
CA2571218A 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof Expired - Fee Related CA2571218C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2897218A CA2897218A1 (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US58051104P 2004-06-17 2004-06-17
US60/580,511 2004-06-17
US60862504P 2004-09-10 2004-09-10
US60/608,625 2004-09-10
US61005404P 2004-09-15 2004-09-15
US60/610,054 2004-09-15
US61873504P 2004-10-14 2004-10-14
US60/618,735 2004-10-14
PCT/US2005/021444 WO2006009836A2 (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2897218A Division CA2897218A1 (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Publications (2)

Publication Number Publication Date
CA2571218A1 CA2571218A1 (en) 2006-01-26
CA2571218C true CA2571218C (en) 2015-11-03

Family

ID=35785692

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2571218A Expired - Fee Related CA2571218C (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof
CA2897218A Abandoned CA2897218A1 (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2897218A Abandoned CA2897218A1 (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Country Status (6)

Country Link
US (4) US8410246B2 (enExample)
EP (3) EP2789342A1 (enExample)
JP (5) JP4971149B2 (enExample)
AU (1) AU2005265098B2 (enExample)
CA (2) CA2571218C (enExample)
WO (1) WO2006009836A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
US8299212B2 (en) * 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
AU2012201060B2 (en) * 2005-09-20 2015-01-22 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
WO2008150550A1 (en) * 2007-06-05 2008-12-11 Cornell University Compounds for enhancing p21 expression and methods of use thereof
DE102007045919B4 (de) 2007-09-26 2018-07-05 Bayer Intellectual Property Gmbh Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
DE102007045957A1 (de) 2007-09-26 2009-04-09 Bayer Cropscience Ag Wirkstoffkombinationen mit insektiziden und akarziden Eigenschaften
DE102007045956A1 (de) 2007-09-26 2009-04-09 Bayer Cropscience Ag Wirkstoffkombination mit insektiziden und akariziden Eigenschaften
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2013013085A2 (en) * 2011-07-19 2013-01-24 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
WO2016010844A1 (en) * 2014-07-14 2016-01-21 Tarix Pharmaceuticals Ltd Methods and compositions for the treatment of stroke
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
US20160137714A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
CA2995310A1 (en) 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
CA2998677A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR20180052705A (ko) * 2015-09-17 2018-05-18 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2017178253A1 (en) 2016-04-13 2017-10-19 Universiteit Maastricht Method for the treatment or prevention of osteoarthritis
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
AU2019366366B2 (en) * 2018-10-22 2025-09-25 William D. Carlson Therapeutic combinations of TDFRPs and additional agents and methods of use
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
EP3981431A4 (en) * 2019-03-14 2023-06-28 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2022020711A1 (en) * 2020-07-24 2022-01-27 The Texas A&M University System Sars-cov-2 main protease inhibitors
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN116286643A (zh) * 2021-03-26 2023-06-23 广西大学 一种体外高效诱导人体细胞重编程为神经元细胞的方法
EP4601667A1 (en) * 2022-10-10 2025-08-20 Therapeutics by Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury
CN117045795B (zh) * 2023-08-11 2026-01-09 中南大学湘雅三医院 一种Hedgehog通路抑制剂在防治动脉搭桥术后并发症的制药用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4768523A (en) 1981-04-29 1988-09-06 Lifecore Biomedical, Inc. Hydrogel adhesive
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5092871A (en) 1987-03-13 1992-03-03 Brown University Research Foundation Electrically-charged nerve guidance channels
US5041126A (en) 1987-03-13 1991-08-20 Cook Incorporated Endovascular stent and delivery system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4955892A (en) 1988-10-24 1990-09-11 Louisiana State University Neural cell adhesion protein nerve prosthesis
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH085780B2 (ja) 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5052998A (en) 1990-04-04 1991-10-01 Zimmon David S Indwelling stent and method of use
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
WO1992000968A1 (en) 1990-07-10 1992-01-23 Smithkline Beecham Corporation Oxamides
EP0573608A1 (en) 1991-02-07 1993-12-15 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69231062T3 (de) 1991-08-30 2004-07-29 Creative Biomolecules, Inc., Hopkinton Morphogen-induzierte Modulation von entzündlichen Antworten
EP1637156A1 (en) 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
US5683448A (en) 1992-02-21 1997-11-04 Boston Scientific Technology, Inc. Intraluminal stent and graft
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
AU681594B2 (en) 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
EP0680334B1 (en) 1992-09-15 2000-12-13 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
CA2144514C (en) 1992-09-16 2002-03-26 Thangavel Kuberasampath Morphogen-induced liver regeneration
JP3537141B2 (ja) 1992-10-30 2004-06-14 ザ ゼネラル ホスピタル コーポレーション 新種蛋白質分離のための相互作用を用いる補捉システム
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
US5579591A (en) 1993-06-29 1996-12-03 Limited Responsibility Company Frontier Footwear for patients of osteoarthritis of the knee
NZ278765A (en) 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5614609A (en) 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5681274A (en) 1995-03-31 1997-10-28 Boston Scientific Corporation Variable length uretheral stent
US5569676A (en) 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
JP2000514777A (ja) 1995-08-14 2000-11-07 クリエイティブ バイオモレキュールズ，インコーポレイテッド 骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合
US5989827A (en) 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US6273598B1 (en) * 1996-01-22 2001-08-14 Creative Biomolecules, Inc. Computer system and methods for producing morphogen analogs of human OP-1
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
ATE493141T1 (de) 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
WO1998040747A1 (en) 1997-03-07 1998-09-17 Mount Sinai Hospital Corporation Methods to diagnose a required regulation of trophoblast invasion
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6198281B1 (en) 1997-11-12 2001-03-06 The Research Foundation Of State University Of New York NMR spectroscopy of large proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP3561738B2 (ja) 1998-06-02 2004-09-02 株式会社リガク Ｂｒａｇｇ反射自動選出方法および装置並びに結晶方位自動決定方法およびシステム
EP1100872A1 (en) 1998-07-24 2001-05-23 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-beta family of growth factors
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
US6329184B1 (en) 1998-12-18 2001-12-11 Pharmacia & Upjohn Ab Crystalline form of activated tartrate-resistant and purple acid phosphatase
US6444802B1 (en) 1999-09-30 2002-09-03 Millenium Pharmaceuticals, Inc. Human aminopeptidase
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6468346B2 (en) 1999-12-10 2002-10-22 Bsi Proteomics Corporation Applying x-ray topography and diffractometry to improve protein crystal growth
US20040171533A1 (en) 2000-02-29 2004-09-02 Barbara Zehentner Methods and compositions for regulating adiopocytes
US6669722B2 (en) 2000-09-22 2003-12-30 Cordis Corporation Stent with optimal strength and radiopacity characteristics
EP1334365B1 (en) 2000-11-06 2007-02-21 Thrasos, Inc. Screening methods for bone morphogenetic mimetics
EP1334442A2 (en) 2000-11-06 2003-08-13 Thrasos, Inc. Computer method and apparatus for classifying objects
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US6679911B2 (en) 2001-03-01 2004-01-20 Cordis Corporation Flexible stent
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
US6673106B2 (en) 2001-06-14 2004-01-06 Cordis Neurovascular, Inc. Intravascular stent device
US20030103959A1 (en) 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor
WO2003106972A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Multiple domain tdf-related compounds and analogs thereof
EP1572950B1 (en) * 2002-06-17 2012-10-10 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
US20040093164A1 (en) 2002-11-08 2004-05-13 Carlson William D. Computer system and methods for producing morphogen analogs of human TDF-1
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
JP5829193B2 (ja) 2015-12-09
WO2006009836A3 (en) 2007-08-23
CA2897218A1 (en) 2006-01-26
JP2012019788A (ja) 2012-02-02
CA2571218A1 (en) 2006-01-26
US20100015150A1 (en) 2010-01-21
WO2006009836A2 (en) 2006-01-26
JP2016155855A (ja) 2016-09-01
JP5513449B2 (ja) 2014-06-04
US20160152674A1 (en) 2016-06-02
AU2005265098A1 (en) 2006-01-26
JP2015013894A (ja) 2015-01-22
US9181301B2 (en) 2015-11-10
EP1773871A2 (en) 2007-04-18
EP1773871B1 (en) 2014-10-15
US8410246B2 (en) 2013-04-02
US20140044754A1 (en) 2014-02-13
EP2319526A1 (en) 2011-05-11
JP4971149B2 (ja) 2012-07-11
US8916686B2 (en) 2014-12-23
AU2005265098B2 (en) 2012-02-23
US20150132355A1 (en) 2015-05-14
JP2008512087A (ja) 2008-04-24
JP2013034477A (ja) 2013-02-21
EP2789342A1 (en) 2014-10-15
EP1773871A4 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
US9181301B2 (en) TDF-related compounds and analogs thereof
US8911953B2 (en) TDF-related compounds and analogs thereof, analogs and bioactive fragments
AU2012201060B2 (en) TDF-related compounds and analogs thereof
AU2012200042B2 (en) TDF-related compounds and analogs thereof
AU2015200812A1 (en) TDF-related compounds and analogs thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180618